All the latest FDA news and information you need to know.
Approval of Currently Unapproved Medicines
On Oct. 17, the FDA announced that it will aggressively crack down on the marketing of unapproved drug products. At the same time, the agency proposed new steps to assure the safety and efficacy of certain unapproved but widely marketed medicines.
ENJOY UNLIMITED ACCESS TO THE SINGLE SOURCE OF OBJECTIVE LEGAL ANALYSIS, PRACTICAL INSIGHTS, AND NEWS IN LawJournalNewsletters
Already have an account? Sign In Now
For enterprise-wide or corporate access, please contact Customer Service at [email protected] or call 1-877-256-2473.
NOT FOR REPRINT
© 2026 ALM Global, LLC, All Rights Reserved. Request academic re-use from www.copyright.com. All other uses, submit a request to [email protected]. For more information visit Asset & Logo Licensing.
The Copyright Royalty Board (CRB), which works under the umbrella of the Librarian of Congress, sets statutory-license royalty terms and rates. The U.S. Courts of Appeals for the D.C. Circuit recently issued two notable decisions about the CRB.
As quantum machines become more powerful, today’s uncrackable encryption schemes may become trivial to break. Opinions vary as to how soon that moment, so-called “Q Day,” will arrive, but the threat is real.
How do you communicate when you know the harm before you know its cause? For law firms, it comes up both when advising a client and when explaining an incident of their own.
The gap between what a firm bills and what it collects is not a collections failure. It is a design flaw in how the whole revenue cycle is wired, and clients armed with AI are now exploiting it faster than firms can respond.
© Copyright 2026 ALM Global, LLC trading as Centellic.
Advertise with Us Customer Support Terms of Service Privacy Policy
